SCHEMBL20636784

SCHEMBL20636784

Oc1nc2cc(C(F)(F)F)cc(Cl)c2nc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF20B Q96Q89 1/20 0.48
GLP1R P43220 1/20 0.47
CBFB Q13951 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 3/20 0.37
EGLN1 Q9GZT9 1/20 0.35
PLAU P00749 1/20 0.35
PDE2A O00408 1/20 0.34
GABRB3 P28472 2/20 0.34
GABRA2 P47869 2/20 0.34
GABRB2 P47870 2/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRE P78334 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660278 0.74 KIF20B (0.50) KIF20BGLP1RCBFBKDM4EALDH1A1
SCHEMBL11215259 0.72 THRB (0.46) KDM4EALDH1A1GAAHTTRAB9A
SCHEMBL9534239 0.71 CSNK2A1 (0.38) KDM4EALDH1A1GAAHTTPOLB
SCHEMBL12413060 0.70 GLP1R (0.38) KIF20BGLP1RKDM4EALDH1A1PDE2A
SCHEMBL6107899 0.69 KDM4E (0.72) KDM4E
SCHEMBL5600053 0.69 ALDH1A1 (0.50) KDM4EALDH1A1PLAUPDE2AGAA
SCHEMBL12377307 0.67 PDE2A (0.38) KIF20BGLP1RKDM4EALDH1A1PDE2A
SCHEMBL9534757 0.67 MMP14 (0.33) KDM4EALDH1A1HTTMAPT
SCHEMBL1971207 0.66 ALDH1A1 (0.58) KDM4EALDH1A1PLAUGAAHTT
SCHEMBL23689905 0.66 KIF20B (0.39) KIF20BGLP1RCBFBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288544-A1 PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) 2025-09-18 US disclosed
US-12318358-B2 Probenecid for use in treating epileptic diseases, disorders or conditions PARIS SCIENCES ET LETTRES (FR) 2025-06-03 US disclosed
CN-111386107-A Use of probenecid in the treatment of an epileptic disease, disorder or condition 巴黎科技与文学─拉丁区 2020-07-07 CN disclosed
US-20200163916-A1 PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) 2020-05-28 US disclosed
EP-3651758-A1 PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS Paris Sciences et Lettres - Quartier Latin (FR) 2020-05-20 EP disclosed
WO-2019012109-A1 PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) 2019-01-17 WO disclosed
EP-3427729-A1 PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS Paris Sciences et Lettres - Quartier Latin (FR) 2019-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200163916-A1 PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS NLN, CLN6, SLC1A2 KIF20B 1453/4885GLP1R 3503/4885CBFB 4345/4885
US-20250288544-A1 PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS NLN, CLN6, SLC1A2 KIF20B 1453/4885GLP1R 3503/4885CBFB 4345/4885
US-12318358-B2 Probenecid for use in treating epileptic diseases, disorders or conditions NLN, CLN6, SLC1A2 KIF20B 1453/4885GLP1R 3503/4885CBFB 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.